Jonathan Young Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 12,500 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $47.79, for a total value of $597,375.00. Following the sale, the chief operating officer owned 197,484 shares of the company’s stock, valued at approximately $9,437,760.36. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Wednesday, June 18th, Jonathan Young sold 1,453 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.84, for a total value of $79,682.52.
• On Tuesday, June 10th, Jonathan Young sold 2,493 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.99, for a total value of $134,597.07.

Akero Therapeutics Stock Performance

NASDAQ AKRO opened at $49.38 on Friday. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of -24.69 and a beta of -0.28. The company has a quick ratio of 16.80, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $51.95 and a 200-day moving average price of $47.32. Akero Therapeutics, Inc. has a twelve month low of $21.34 and a twelve month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.11. During the same period in the prior year, the business posted ($0.81) earnings per share. As a group, equities research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AKRO has been the subject of a number of research reports. Bank of America upped their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, May 27th. Wall Street Zen raised Akero Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Citigroup cut their price target on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. TD Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating and a $76.00 price target for the company. Finally, Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $81.57.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds have recently made changes to their positions in AKRO. PNC Financial Services Group Inc. lifted its position in shares of Akero Therapeutics by 17.7% in the second quarter. PNC Financial Services Group Inc. now owns 1,952 shares of the company’s stock worth $104,000 after buying an additional 294 shares in the last quarter. GF Fund Management CO. LTD. lifted its position in shares of Akero Therapeutics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock worth $72,000 after buying an additional 321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Akero Therapeutics by 14.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock worth $114,000 after buying an additional 338 shares in the last quarter. Amalgamated Bank lifted its position in shares of Akero Therapeutics by 19.0% in the first quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after buying an additional 410 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in shares of Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after buying an additional 450 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.